{"entity":{"id":"inge-marie-svane","kind":"person","name":"Inge Marie Svane","aka":[],"tldr":"Led the Dutch-Danish trial that proved TIL therapy beats ipilimumab in melanoma, the first randomised win for a cell therapy in a solid tumour.","summary":"Inge Marie Svane (Herlev, Denmark) co-led with John Haanen the randomised phase 3 trial showing tumour-infiltrating lymphocyte therapy doubles progression-free survival compared with ipilimumab in advanced melanoma, the first randomised evidence for any cell therapy in a solid tumour. She built Denmark's academic TIL manufacturing programme and leads trials of TIL in other cancers and of peptide vaccines targeting IDO and PD-L1.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Svane%20IM%5BAuthor%5D%20tumor-infiltrating%20lymphocytes%20melanoma"}],"tags":["cell-therapy","til","melanoma"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["til-therapy"],"targets":[],"drugs":["lifileucel","ipilimumab"],"companies":[],"institutions":["herlev-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-rohaas-til-vs-ipilimumab-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Director, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital Herlev","institutionId":"herlev-hospital","specialisms":["Tumour-infiltrating lymphocyte therapy","Melanoma immunotherapy","Cancer vaccines","Cell therapy manufacturing"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Svane%20IM%5BAuthor%5D%20tumor-infiltrating%20lymphocytes%20melanoma"}],"papers":[{"title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2210233"},{"title":"Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen","journal":"Clinical Cancer Research","year":2016,"doi":"10.1158/1078-0432.CCR-15-1879"}],"orcid":"0000-0002-9451-6037"},"route":"/people/inge-marie-svane/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"technology":[{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"lifileucel","kind":"drug","name":"Lifileucel","route":"/drugs/lifileucel/"}],"institution":[{"id":"herlev-hospital","kind":"institution","name":"Herlev Hospital, Copenhagen University Hospital","route":"/institutions/herlev-hospital/"}],"paper":[{"id":"paper-rohaas-til-vs-ipilimumab-nejm-2022","kind":"paper","name":"Rohaas 2022: the first randomised trial of TIL therapy, against ipilimumab, in advanced melanoma","route":"/key-papers/paper-rohaas-til-vs-ipilimumab-nejm-2022/"}]}}